Brentuximab (Anti-TNFRSF8 / CD30) is a humanized chimeric monoclonal antibody targeting anti-CD30 with antineoplastic activity. The antibody-drug conjugate (ADC) Brentuximab vedotin, marketed under the brand name Adcetris, is medicine used primarily to treat certain types of lymphoma, including Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL). This ADC drug is a conjugate that combines a monoclonal antibody Brentuximab, linker and cytotoxic agent monomethyl auristatin E (MMAE). It targets the CD30 antigen on cancer cells, delivering the MMAE directly to these cells to help destroy them. This biosimilar antibody is used for research only. MW: 145.38 KD.
Product Details |
Species Reactivity | Human |
---|
Host/Isotype | Human IgG1 |
---|
Class | Monoclonal |
---|
Type | Recombinant Antibody |
---|
Immunogen | Human TNFRSF8/CD30 |
---|
Clone | Brentuximab biosimilar |
---|
Conjugate | Unconjugated |
---|
Purity | 99% |
---|
Molecular Weight | 145.38 KD |
---|
Protein Concentration | 1mg/ml |
---|
Storage Condition | Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
---|
Storage Buffer | 100mM Pro-Ac, 20mM Arg-Ac, pH 5.0 |